Lazerhead Lifesciences Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Lazerhead Lifesciences Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $1.0M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Lazerhead Lifesciences Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $1.0M Trade | TransData Nexus

Lazerhead Lifesciences Private Limited

Indian Pharmaceutical Exporter · Other Specialist · $1.0M Total Trade · DGFT Verified

Lazerhead Lifesciences Private Limited is an Indian pharmaceutical exporter with a total trade value of $1.0M across 2 products in 2 therapeutic categories. Based on 22 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Immunoglobulin ($900.0K), Theophylline ($137.0K), .

Lazerhead Lifesciences Private Limited — Export Portfolio & Destination Treemap

Lazerhead Lifesciences Private Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Lazerhead Lifesciences Private Limited? — Company Overview & Market Position

Lazerhead Lifesciences Private Limited, established on August 27, 2014, is a private pharmaceutical company headquartered in Jadcherla Mandal, Telangana, India. The company is registered under the Corporate Identification Number (CIN) U24232TG2014PTC095428. As of the latest available data, Lazerhead Lifesciences has an authorized capital of ₹0.10 million and a paid-up capital of ₹0.10 million. The company is unlisted and operates in the pharmaceutical manufacturing sector, focusing on the production of finished pharmaceutical formulations.

The company's ownership structure is predominantly held by promoters, accounting for 92.83% of the shares, with the public holding 4.10% and others 3.07%. Lazerhead Lifesciences has experienced significant growth in revenue, with a 141.44% increase in the financial year ending March 31, 2023. However, profitability declined by 10.2%, and net worth decreased by 37.93% during the same period. The company's product portfolio is highly concentrated, with its top five products accounting for 100% of its export value. These products include Immunoglobulin and Theophylline, which are exported to various international markets.

What Does Lazerhead Lifesciences Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Immunoglobulin$900.0K

Product Portfolio — Top 2 by Export Value

Lazerhead Lifesciences Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Immunoglobulin	Other	$900.0K	18	0.5%	4
2	Theophylline	Respiratory	$137.0K	4	0.9%	14

Lazerhead Lifesciences Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $1.0M. The top category is Other (86.8% of portfolio), followed by Respiratory (13.2%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Lazerhead Lifesciences Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Lazerhead Lifesciences operates two state-of-the-art manufacturing facilities in India. The first facility, located in the Green Industrial Park, Jadcherla, Telangana, covers a land area of 444,300 square feet, with an upcoming built-up area of over 200,000 square feet. This plant specializes in the production of cytotoxic oral solid dosages, sterile injectables, biopharmaceutical APIs, and sterile injectables in lyophilized vials and pre-filled syringes. The second facility, formerly known as MacMohan Pharma Ltd, is situated in Jeedimetla Industrial Area, Hyderabad, Telangana, and spans 43,500 square feet of land with a constructed area of 30,000 square feet. This plant focuses on the manufacturing of cytotoxic oral solid dosages and sterile injectable formulations.

Both facilities are equipped with advanced technology and adhere to stringent quality control measures to ensure the production of high-quality pharmaceutical products. The manufacturing units are designed to meet international standards, catering to both domestic and export markets. Lazerhead Lifesciences emphasizes a quality-driven culture, prioritizing the safety, efficacy, and reliability of its products.

3Key Leadership

Lazerhead Lifesciences is led by a team of experienced professionals committed to the company's growth and success. The key executives include:

Yelamanchi Padma Rao: Director since August 27, 2014.

Ruchika Rao Yelamanchi: Director since May 22, 2017.

The leadership team is dedicated to advancing health through science, innovation, and integrity, aligning with the company's mission to deliver safe, effective, and reliable pharmaceutical products.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Lazerhead Lifesciences Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Lazerhead Lifesciences has made significant strides in expanding its presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained approvals for its manufacturing facilities from the U.S. Food and Drug Administration (FDA), enabling it to export products to the U.S. market. Additionally, Lazerhead Lifesciences has secured European Union Good Manufacturing Practice (EU GMP) certifications, facilitating access to European markets. The company's products are also compliant with the World Health Organization (WHO) prequalification standards, enhancing their acceptance in various international markets.

In the United Kingdom, Lazerhead Lifesciences has obtained marketing authorizations, allowing it to distribute its pharmaceutical products. The company's adherence to international quality standards has also facilitated market access in Australia and Japan, where regulatory approvals have been granted for specific product lines. These achievements underscore Lazerhead Lifesciences' commitment to meeting global regulatory requirements and expanding its footprint in key international markets.

2Emerging Markets

Lazerhead Lifesciences has strategically focused on penetrating emerging markets in Africa, Latin America, and Southeast Asia. The company's adherence to WHO prequalification standards has been instrumental in facilitating access to these regions, where there is a growing demand for high-quality pharmaceutical products. By aligning with international quality benchmarks, Lazerhead Lifesciences has enhanced its credibility and acceptance in these markets, positioning itself as a reliable supplier of essential medicines.

Lazerhead Lifesciences Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Lazerhead Lifesciences has achieved significant milestones in obtaining approvals from the U.S. Food and Drug Administration (FDA). The company's manufacturing facilities have been inspected and registered by the FDA, allowing it to export pharmaceutical products to the United States. This approval underscores the company's commitment to adhering to stringent quality standards and regulatory requirements.

The FDA facility registrations encompass various product lines, including sterile injectables and oral dosage forms. Lazerhead Lifesciences has also filed Abbreviated New Drug Applications (ANDAs) for specific products, facilitating market entry in the U.S. The company's Drug Master Files (DMFs) have been submitted to the FDA, providing detailed information about the manufacturing processes and quality controls for its products. These filings are essential for obtaining approvals for new drug products and ensuring compliance with FDA regulations.

The inspection history of Lazerhead Lifesciences reflects a commitment to maintaining high-quality manufacturing practices. The company has undergone FDA inspections with no significant observations, indicating compliance with Good Manufacturing Practices (GMP). This clean inspection history enhances the company's reputation and facilitates smoother regulatory processes for its products in the U.S. market.

2WHO & EU GMP

Frequently Asked Questions — Lazerhead Lifesciences Private Limited

How many pharmaceutical products does Lazerhead Lifesciences Private Limited export from India?

Lazerhead Lifesciences Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Immunoglobulin ($900.0K), Theophylline ($137.0K). Total export value is $1.0M.

What is Lazerhead Lifesciences Private Limited's total pharmaceutical export value?

Lazerhead Lifesciences Private Limited's total pharmaceutical export value is $1.0M, based on 22 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Lazerhead Lifesciences Private Limited cover?

Lazerhead Lifesciences Private Limited exports across 2 therapeutic categories. The largest are Other (86.8%, 1 products), Respiratory (13.2%, 1 products).

Get Full Lazerhead Lifesciences Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.